81588 methods and compositions of human proteins and uses thereof
AssigneeMillennium Pharmaceuticals, Inc.
InventorsKevin Leiby, Rosana Kapeller-Libermann, Maria Glucksmann
Life of this patent
Estimating the term…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsKevin Leiby, Rosana Kapeller-Libermann, Maria Glucksmann
Estimating the term…
The invention provides isolated nucleic acids molecules, designated 38650, 28472, 5495, 65507, 81588 or 14354 nucleic acid molecules, which encode novel adenosine deaminase, glycoprotease, or seven transmembrane receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38650, 28472, 5495, 65507, 81588 or 14354 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38650, 28472, 5495, 65507, 81588 or 14354 gene has been introduced or disrupted. The invention still further provides isolated 38650, 28472, 5495, 65507, 81588 or 14354 proteins, fusion proteins, antigenic peptides and anti-38650, 28472, 5495, 65507, 81588 or 14354 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
An isolated 81588 nucleic acid molecule selected from the group consisting of:
An isolated 81588 polypeptide selected from the group consisting of:
A method for identifying a compound capable of treating a disorder characterized by aberrant 81588 nucleic acid expression or 81588 polypeptide activity comprising assaying the ability of the compound to modulate 81588 nucleic acid expression or 81588 polypeptide activity, thereby identifying a compound capable of treating a disorder characterized by aberrant 81588 nucleic acid expression or 81588 polypeptide activity.
18-21. (canceled)
Dependencies are inferred from the claim text.